Sargramostim
- Generic Name
- Sargramostim
- Brand Names
- Leukine
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 123774-72-1
- Unique Ingredient Identifier
- 5TAA004E22
- Background
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
- Indication
For the treatment of cancer and bone marrow transplant
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Hematopoietic Subsyndrome of Acute Radiation Syndrome, Hodgkin's Lymphoma, Neutropenia, Non-Hodgkin's Lymphoma (NHL), Severe Infection
- Associated Therapies
- Allogenic bone marrow transplantation therapy, Autologous bone marrow transplantation therapy, Autologous peripheral haematopoietic stem cell transplant
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyBiological: DinutuximabProcedure: FDG-Positron Emission TomographyRadiation: Iobenguane I-123Drug: IrinotecanDrug: IsotretinoinProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanBiological: SargramostimDrug: Temozolomide
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 41
- Registration Number
- NCT04385277
- Locations
- ๐บ๐ธ
Nationwide Children's Hospital, Columbus, Ohio, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธBaylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- University Hospital, Ghent
- Target Recruit Count
- 87
- Registration Number
- NCT04326920
- Locations
- ๐ง๐ช
AZ Sint Jan Brugge, Brugge, Belgium
๐ง๐ชUniversity Hospital Ghent, Gent, Belgium
๐ง๐ชAZ Delta Roeselare, Roeselare, Belgium
GM-CSF With Post-Transplant Cyclophosphamide
- Conditions
- Interventions
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT04237623
- Locations
- ๐บ๐ธ
Northside Hospital, Atlanta, Georgia, United States
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
- Conditions
- Interventions
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Nationwide Children's Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT04211675
- Locations
- ๐บ๐ธ
Nationwide Children's Hospital, Columbus, Ohio, United States
Using a Targeted Cancer Vaccine (Galinpepimut-S) with Immunotherapy (Nivolumab) in Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT04040231
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
๐บ๐ธMemorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center @ Commack, Commack, New York, United States
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
- Conditions
- Interventions
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- David Peereboom
- Target Recruit Count
- 41
- Registration Number
- NCT04013672
- Locations
- ๐บ๐ธ
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 14
- Registration Number
- NCT03879694
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 95
- Registration Number
- NCT03794349
- Locations
- ๐บ๐ธ
Connecticut Children's Medical Center, Hartford, Connecticut, United States
๐บ๐ธYale University, New Haven, Connecticut, United States
๐บ๐ธChildren's National Medical Center, Washington, District of Columbia, United States
Biomarker Assessments of Leukine During Treatment of Parkinson's Disease
- First Posted Date
- 2019-01-02
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 7
- Registration Number
- NCT03790670
- Locations
- ๐บ๐ธ
University of Nebraska Medical Center, Omaha, Nebraska, United States
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
- Conditions
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CarboplatinDrug: CisplatinDrug: CyclophosphamideDrug: DexrazoxaneBiological: DinutuximabDrug: DoxorubicinDrug: EtoposideRadiation: External Beam Radiation TherapyDrug: IsotretinoinDrug: MelphalanBiological: SargramostimDrug: ThiotepaDrug: TopotecanDrug: Vincristine
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT03786783
- Locations
- ๐บ๐ธ
Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
๐ณ๐ฟStarship Children's Hospital, Grafton, Auckland, New Zealand
๐ฆ๐บThe Children's Hospital at Westmead, Westmead, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.